Clinical trial
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (13 to 17 Years of Age)
NCT07288567 is registered in ClinicalTrials.gov with Bristol-Myers Squibb as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (13 to 17 Years of Age)
- Lead sponsor
- Bristol-Myers Squibb
- Phase
- Phase 3
- Overall status
- Recruiting
- Start date
- January 29, 2026
- Completion date
- December 18, 2029
- Enrollment
- 166 (estimated)
- Sites
- 37
Conditions
As the registry lists them; a condition with its own page is linked.